ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...

Arecor: Business Update Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...

BUSINESS UPDATE Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...

ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP First patient dosed in potential...

ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER...